ENTX
Price
$1.94
Change
-$0.01 (-0.51%)
Updated
Aug 26, 11:16 AM (EDT)
Capitalization
88.59M
72 days until earnings call
XENE
Price
$38.14
Change
-$0.70 (-1.80%)
Updated
Aug 25 closing price
Capitalization
2.94B
71 days until earnings call
Interact to see
Advertisement

ENTX vs XENE

Header iconENTX vs XENE Comparison
Open Charts ENTX vs XENEBanner chart's image
Entera Bio
Price$1.94
Change-$0.01 (-0.51%)
Volume$170
Capitalization88.59M
Xenon Pharmaceuticals
Price$38.14
Change-$0.70 (-1.80%)
Volume$460.03K
Capitalization2.94B
ENTX vs XENE Comparison Chart in %
Loading...
ENTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTX vs. XENE commentary
Aug 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTX is a StrongBuy and XENE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 26, 2025
Stock price -- (ENTX: $1.95 vs. XENE: $38.14)
Brand notoriety: ENTX and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTX: 32% vs. XENE: 38%
Market capitalization -- ENTX: $88.59M vs. XENE: $2.94B
ENTX [@Biotechnology] is valued at $88.59M. XENE’s [@Biotechnology] market capitalization is $2.94B. The market cap for tickers in the [@Biotechnology] industry ranges from $99.72B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTX’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • ENTX’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than ENTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTX’s TA Score shows that 7 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • ENTX’s TA Score: 7 bullish, 2 bearish.
  • XENE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ENTX is a better buy in the short-term than XENE.

Price Growth

ENTX (@Biotechnology) experienced а -2.50% price change this week, while XENE (@Biotechnology) price change was +0.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.46%. For the same industry, the average monthly price growth was +23.43%, and the average quarterly price growth was +29.28%.

Reported Earning Dates

ENTX is expected to report earnings on Nov 06, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+1.46% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.94B) has a higher market cap than ENTX($88.6M). XENE YTD gains are higher at: -2.704 vs. ENTX (-8.019). ENTX has higher annual earnings (EBITDA): -10.55M vs. XENE (-315.5M). XENE has more cash in the bank: 488M vs. ENTX (10.9M). ENTX has less debt than XENE: ENTX (203K) vs XENE (8.72M). XENE has higher revenues than ENTX: XENE (7.5M) vs ENTX (166K).
ENTXXENEENTX / XENE
Capitalization88.6M2.94B3%
EBITDA-10.55M-315.5M3%
Gain YTD-8.019-2.704297%
P/E RatioN/AN/A-
Revenue166K7.5M2%
Total Cash10.9M488M2%
Total Debt203K8.72M2%
FUNDAMENTALS RATINGS
ENTX vs XENE: Fundamental Ratings
ENTX
XENE
OUTLOOK RATING
1..100
2920
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
9638
SMR RATING
1..100
9996
PRICE GROWTH RATING
1..100
5843
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ENTX's Valuation (73) in the Pharmaceuticals Major industry is in the same range as XENE (75) in the Biotechnology industry. This means that ENTX’s stock grew similarly to XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (38) in the Biotechnology industry is somewhat better than the same rating for ENTX (96) in the Pharmaceuticals Major industry. This means that XENE’s stock grew somewhat faster than ENTX’s over the last 12 months.

XENE's SMR Rating (96) in the Biotechnology industry is in the same range as ENTX (99) in the Pharmaceuticals Major industry. This means that XENE’s stock grew similarly to ENTX’s over the last 12 months.

XENE's Price Growth Rating (43) in the Biotechnology industry is in the same range as ENTX (58) in the Pharmaceuticals Major industry. This means that XENE’s stock grew similarly to ENTX’s over the last 12 months.

XENE's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for ENTX (100) in the Pharmaceuticals Major industry. This means that XENE’s stock grew significantly faster than ENTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTXXENE
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
86%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
74%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 5 days ago
72%
Declines
ODDS (%)
Bearish Trend 20 days ago
89%
Bearish Trend 8 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 6 days ago
86%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ENTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ALARX53.03N/A
N/A
Alger Capital Appreciation Instl I
PNGYX17.12N/A
N/A
Putnam International Value Y
PISDX16.43N/A
N/A
Columbia Pyrford International Stock A
SHXAX15.45-0.05
-0.32%
American Beacon Shapiro Equity Opps A
AGVGX26.98-0.19
-0.70%
American Funds Global Insight F-2

ENTX and

Correlation & Price change

A.I.dvisor tells us that ENTX and JSPR have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ENTX and JSPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTX
1D Price
Change %
ENTX100%
+0.52%
JSPR - ENTX
32%
Poorly correlated
+1.02%
STOK - ENTX
32%
Poorly correlated
-3.53%
OPORF - ENTX
31%
Poorly correlated
N/A
DNLI - ENTX
30%
Poorly correlated
+0.52%
XENE - ENTX
30%
Poorly correlated
-1.80%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-1.80%
IDYA - XENE
59%
Loosely correlated
-1.63%
CRNX - XENE
55%
Loosely correlated
-2.68%
ATXS - XENE
53%
Loosely correlated
-5.45%
NRIX - XENE
52%
Loosely correlated
-4.64%
OCUL - XENE
50%
Loosely correlated
-3.50%
More